- Home
- XGN vs AADI Comparison
XGN vs AADI Comparison
Compare XGN & AADI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- AADI
- Stock Information
- Founded
- XGN 2002
- AADI 2011
- Country
- XGN United States
- AADI United States
- Employees
- XGN N/A
- AADI N/A
- Industry
- XGN Medical Specialities
- AADI Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- AADI Health Care
- Exchange
- XGN Nasdaq
- AADI Nasdaq
- Market Cap
- XGN 72.3M
- AADI 59.4M
- IPO Year
- XGN 2019
- AADI N/A
- Fundamental
- Price
- XGN $5.65
- AADI $2.36
- Analyst Decision
- XGN Buy
- AADI Hold
- Analyst Count
- XGN 1
- AADI 3
- Target Price
- XGN $7.00
- AADI $1.75
- AVG Volume (30 Days)
- XGN 189.6K
- AADI 109.6K
- Earning Date
- XGN 11-12-2024
- AADI 11-06-2024
- Dividend Yield
- XGN N/A
- AADI N/A
- EPS Growth
- XGN N/A
- AADI N/A
- EPS
- XGN N/A
- AADI N/A
- Revenue
- XGN $55,751,000.00
- AADI $25,070,000.00
- Revenue This Year
- XGN $6.74
- AADI $9.39
- Revenue Next Year
- XGN $17.32
- AADI $6.15
- P/E Ratio
- XGN N/A
- AADI N/A
- Revenue Growth
- XGN 8.00
- AADI 7.80
- 52 Week Low
- XGN $1.30
- AADI $1.21
- 52 Week High
- XGN $6.22
- AADI $2.63
- Technical
- Relative Strength Index (RSI)
- XGN 74.82
- AADI 58.75
- Support Level
- XGN $5.60
- AADI $2.25
- Resistance Level
- XGN $6.22
- AADI $2.45
- Average True Range (ATR)
- XGN 0.48
- AADI 0.11
- MACD
- XGN 0.13
- AADI -0.01
- Stochastic Oscillator
- XGN 88.00
- AADI 39.89
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About AADI Aadi Bioscience Inc.
Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.